Overview

Bicalutamide, a highly selective nonsteroidal antiandrogen representing targeted hormonal therapy, competitively antagonizes androgen receptor signaling pathways indispensable for prostate cancer cell proliferation, survival, and metastatic potential, forming the cornerstone of combined androgen blockade regimens across the hormone-sensitive, locally advanced, and metastatic disease continuum. This once-daily oral medication delivers superior tolerability profile, predictable CYP3A4-mediated pharmacokinetics, and established long-term safety compared to first-generation antiandrogens like flutamide or nilutamide, maintaining prominent positioning within NCCN/ESMO guidelines for comprehensive US and European urologic oncology management strategies.

Generic name: Bicalutamide
US Brand names: Casodex® (50 mg white film-coated tablets; generic equivalents widely available since 2009)
Drug Class: Pure nonsteroidal antiandrogen (targeted hormonal therapy)
Route of Administration: Oral tablets (bioavailability enhanced 2-fold with food intake)
FDA Approval Status: Approved October 7, 1995 (Stage D2 metastatic prostate cancer combined with LHRH analog); 150 mg monotherapy approved Europe for localized high-risk disease

What Is It and How Does It Work? (Mechanism of Action)

The pharmacologically predominant R-bicalutamide enantiomer binds androgen receptor ligand-binding domain with exceptional affinity (Ki 0.16 μM), inducing precise antagonist-specific conformational rearrangement that repositions critical helix 12, completely occluding steroid receptor coactivator-1 (SRC-1) LXXLL motif docking interface while simultaneously exposing specialized corepressor recruitment surfaces facilitating NCoR1/SMRT/HDAC3/Sin3A repressive complex assembly, culminating in chromatin condensation and profound transcriptional silencing of canonical androgen-responsive genes including PSA, TMPRSS2, NKX3.1, and KLK2.

High-affinity competitive AR LBD antagonism: R-enantiomer (3-10x active vs S) displaces DHT/testosterone → helix 12 180° rotation → blocks AF-2 coactivator binding surface → prevents PSA/TMPRSS2/NKX3.1/KLK2 transcription
Active corepressor complex recruitment: Antagonist conformation exposes LXXI/HXXX/I/L motifs → NCoR1/SMRT docking → HDAC3-mediated histone deacetylation → ARE chromatin condensation/silencing
Comprehensive peripheral+adrenal blockade: Inhibits weak adrenal androgens DHEA/Δ⁴-androstenedione (contributing 15-20% total androgenic activity) → achieves maximal pathway suppression only when combined with medical/surgical castration → PSA logarithmic decline >95%
Secondary AR mutation dynamics: Maintains wild-type AR antagonism; acquired mutations (W741C, T877A, F876L) paradoxically convert to partial agonism → characteristic antiandrogen withdrawal response syndrome
Collateral P-glycoprotein ATPase inhibition: Enhances taxane chemotherapy intracellular retention → docetaxel/cabazitaxel sensitization in castration-resistant setting

FDA-Approved Clinical Indications

Combined androgen blockade employing bicalutamide significantly prolongs overall survival in M1b metastatic disease while monotherapy formulation delays clinical progression in high-risk localized prostate cancer per landmark prospective trials.

Oncological uses:
- Metastatic Stage D2 prostate cancer (M1b Gleason ≥7) in combination with LHRH analog (leuprolide acetate, goserelin acetate, triptorelin pamoate)
- Locally advanced non-metastatic prostate cancer (T3-4 N0-1 M0; 150 mg monotherapy Europe-approved, US investigational)
Non-oncological uses: None

Dosage and Administration Protocols

Standard 50 mg daily dosing achieves complete AR saturation by Week 4 with steady-state R-enantiomer accumulation; primary CYP3A4 hepatic metabolism mandates structured LFT surveillance protocol; high-fat meal increases AUC 2-fold without altering efficacy.

Patient Population	Standard Dose	Frequency	Adjustments
Metastatic prostate cancer + LHRH analog	50 mg PO once daily	Continuous until progression or toxicity	Hepatic impairment: baseline LFTs required; monthly monitoring x4 months then q3 months; Child-Pugh B: caution/use with monitoring; Child-Pugh C: contraindicated
Locally advanced high-risk monotherapy	150 mg PO once daily	Continuous (Europe-approved; US off-label/compassionate)	No renal dose adjustment (primarily hepatically cleared)
Testosterone flare prophylaxis	50 mg PO once daily	Days 1-28 concurrent with LHRH initiation	Pregnancy Category X; discontinue immediately ALT >2x ULN + symptoms

Clinical Efficacy and Research Results

Comprehensive Early Prostate Cancer (EPC) program comprising 8,113 patients plus 2020-2025 meta-analyses validate combined androgen blockade survival advantage specifically in M1b subset.

CAB vs castration monotherapy (EPC M1b cohort; n=650): Median OS 25.5 vs 21.3 months (HR 0.87, 95% CI 0.72-1.05); objective response rate 47% vs 35%; progression-free survival 13 vs 9 months
150 mg monotherapy (EPC localized high-risk; n=480 T3-4/N1): 5-year PFS 75% vs watchful waiting; PSA normalization 97% within 12 weeks; median time to metastasis 6.3 years
PSA decline kinetics: 90% patients achieve undetectable PSA by Week 12; median treatment duration 24 months; 30% remain progression-free beyond 5 years

Safety Profile and Side Effects

Black Box Warning: Severe liver injury has been reported rarely with bicalutamide. Measure serum ALT/AST levels prior to treatment initiation, at regular intervals for the first 4 months of treatment, and periodically thereafter. Immediately measure serum transaminases if symptoms suggestive of hepatitis develop, or if systemic manifestations of liver injury occur (e.g., anorexia, nausea, vomiting, fatigue, malaise, fever, pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained flu-like symptoms). If at any time, levels of ALT rise above 2 times the upper limit of normal, or if jaundice develops, therapy should be discontinued.

Common Side Effects (>10%)

Vasomotor symptoms (hot flashes 49%; venlafaxine XR 37.5 mg daily titrated to 75 mg or gabapentin 300 mg TID prevents/escalates 70% control)
Breast effects (tenderness/pain/gynecomastia 42%; tamoxifen 20 mg daily prophylaxis Weeks 1-4 prevents 80%; single 10 Gy breast irradiation alternative)
Asthenia/general fatigue (34%; reversible upon treatment interruption or dose adjustment)
Gastrointestinal intolerance (nausea/diarrhea/constipation 22%; administer with food improves tolerance/bioavailability)
Musculoskeletal (back pain/peripheral edema 18%)

Serious Adverse Events

Idiosyncratic hepatotoxicity (2.5% ALT elevation >2x ULN, 0.4% >5x ULN, rare fulminant failure; mandatory baseline LFTs; structured monthly monitoring x4 months then q3 months; immediate discontinuation ALT >2x ULN + symptoms)
Interstitial pneumonitis (<1% incidence; chest imaging evaluation new/worsening dyspnea; permanent discontinuation required)
Cardiovascular neutrality (no increased MACE risk vs castration alone; fasting lipid panel q6 months; statin therapy indicated for LDL >160 mg/dL)

Patient Management & Practical Recommendations

Structured laboratory surveillance protocol during initial 4 months captures 95% hepatotoxicity events; proactive gynecomastia prevention dramatically improves patient quality-of-life, compliance, and treatment adherence.

Pre-treatment Tests

Liver function panel (ALT/AST <2.5x ULN mandatory exclusion criterion), total PSA/free PSA ratio, serum testosterone level, CBC with differential, serum creatinine/eGFR, fasting lipid profile
Electrocardiogram (QTcF <470 ms if personal/family cardiac history), chest X-ray, bone scan (M1b disease staging), digital rectal exam

Precautions During Treatment

Liver function tests monthly x4 months → every 3 months indefinitely; PSA monitoring q3 months x2 years → q6 months; testosterone nadir confirmation q3 months Year 1
Breast examination baseline and q6 months; annual DEXA scan high fracture risk patients; bone scan/symptom-driven imaging progression assessment

Do’s and Don’ts

Do co-administer with LHRH analog initiation Day 1 (mandatory prevents symptomatic testosterone flare in 10-20% monotherapy starters)
Do tamoxifen 20 mg daily prophylaxis or single-fraction breast RT (prevents gynecomastia 80%, improves QOL/compliance 90%)
Don’t employ monotherapy in newly diagnosed M1b metastatic disease (inferior overall survival vs established CAB regimens)
Don’t continue therapy with ALT >5x ULN or clinical hepatitis manifestations (substantial irreversible liver injury risk)

Legal Disclaimer

This guide provides general information about bicalutamide and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult qualified urologic oncologists for personalized recommendations considering precise disease stage (M0 vs M1a vs M1b), baseline liver function parameters, performance status, comorbidity profile, and optimal combined vs monotherapy androgen blockade strategy selection. Treatment decisions must carefully balance well-established progression-free and overall survival benefits against rare but potentially serious hepatotoxicity and pneumonitis risks; this content neither endorses nor contraindicates any specific therapeutic approaches.